MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.
[Product Overview]
As GLP-1 agonists gain global traction for weight loss and metabolic control, concerns are rising over unintended muscle loss, particularly among older adults and non-obese individuals.
MyoKi is a peptide-based nutraceutical solution developed to address this need by supporting muscle preservation and functional performance through the selective inhibition of myostatin, a key regulator of muscle atrophy.
Formulated as a once-daily oral supplement, MyoKi offers a convenient, non-invasive option positioned as a complementary solution to GLP-1-based therapies, helping to maintain functional muscle mass and mobility during weight management.
It is designed for aging populations, individuals undergoing weight management, and active consumers seeking to maintain muscle mass, strength, and overall body composition.
Notably, MyoKi successfully completed the U.S. FDA New Dietary Ingredient (NDI) notification in February 2025, becoming the first myostatin-inhibiting synthetic peptide to receive this designation, and operates through a non-hormonal mechanism, reinforcing its safety profile and positioning it as a globally compliant and scientifically validated ingredient.
[Human Clinical Results]
MyoKi was evaluated in a clinical study involving 80 patients with sarcopenia. The study demonstrated improvements in skeletal muscle mass (+2.52%), lean muscle mass (+2.56%), grip strength (+5.6–6.2%), and 6-meter walk test performance (+12.4%). Biomarker analysis showed increased anabolic activity and reduced catabolic signaling. These results suggest that MyoKi supports muscle regeneration, functional strength, and muscle mass preservation in the context of weight management and healthy aging.
